Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Inhibition of CDK Activity

Inhibition of CDK Activity

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

Positive Regulator Molecules

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Knowledge of gross human anatomy among Brazilian physical education students: A cross-sectional study.

Morphologie : bulletin de l'Association des anatomistes·2025

Same author

How do Patients and Managers Value Gold Standard Elements in Primary Health Care.

Journal of patient experience·2024

Same author

Coastal warming under climate change: Global, faster and heterogeneous.

The Science of the total environment·2023

Same author

Cloning and molecular properties of a novel luciferase from the Brazilian Bicellonycha lividipennis (Lampyridae: Photurinae) firefly: comparison with other firefly luciferases.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2022

Same author

Effects of residential greenness on attention in a longitudinal study at 8 and 11-13 years.

Environmental research·2022

Same author

PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells.

Journal of endocrinological investigation·2022

Search research articles

Related Experiment Video

Updated: Mar 12, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

P27/CDKN1B Translational Regulators in Pituitary Tumorigenesis.

C S Martins¹, R C Camargo², F P Saggioro³

¹Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme

|November 9, 2016

Summary

Pituitary tumors show decreased P27 protein, but this is not due to changes in key translational regulators like DKC1 or RPS13. Further research into DKC1 variants is warranted for pituitary tumor development insights.

More Related Videos

Analysis of Cell Cycle Position in Mammalian Cells

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Related Experiment Videos

Last Updated: Mar 12, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Analysis of Cell Cycle Position in Mammalian Cells

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Area of Science:

Endocrinology
Molecular Biology
Oncology

Background:

P27 (CDKN1B) protein is frequently underexpressed in pituitary tumors.
The underlying mechanisms, particularly translational regulation, require further investigation.

Purpose of the Study:

To investigate whether translational regulation contributes to P27 (CDKN1B) underexpression in pituitary adenomas.
To evaluate the expression of P27 targets and key translational regulators (DKC1, RPS13, miR221, miR222).
To screen for DKC1 gene variants in pituitary adenomas.

Main Methods:

Gene and protein expression analysis (RT-PCR, immunohistochemistry) of P27/CDKN1B, CCNE1, CDK2, DKC1, RPS13, miR221, and miR222 in 48 pituitary adenomas and 7 normal pituitaries.
Sequencing of all 15 exons of the DKC1 gene.
In silico analysis of identified DKC1 variants.

Main Results:

P27 protein underexpression was confirmed across all pituitary adenoma subtypes.
CCNE1 mRNA was overexpressed in nonfunctioning pituitary adenomas (NFPA), but not at the protein level.
No significant differential gene expression was found for RPS13, DKC1, miR221, or miR222 among the groups.
Frequent DKC1 single nucleotide polymorphisms (SNPs) were observed, along with rare variants in 11% of tumors, though in silico analysis suggested no deleterious effects.

Conclusions:

P27 protein underexpression in pituitary adenomas is confirmed, likely involving post-translational mechanisms.
The expression of P27 translational regulators (DKC1, RPS13, miR221, miR222) does not explain P27 underexpression.
DKC1 variants are prevalent in pituitary adenomas but their direct role in tumorigenesis remains unclear.